Figure 1. Proportion of patients with each type of GH stimulation test administered at 2-year intervals of HypoCCS in Italy
• The overall median (quartiles) GH peak concentration reported from GH releasing hormone (GHRH)-arginine stimulation tests was 1.5 (0.5-3.4) µg/L. • The median (quartiles) GH peak concentration from all other stimulation tests was 0.6 (0.2-1.5) µg/L. • The GHRH-arginine test became the most frequent GH stimulation test used in Italian adult patients entered into HypoCCS (Figure 1 ).
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Paolo • In adult patients treated with GH in HypoCCS in Italy, the most frequent GH stimulation test used for diagnosis was GHRHarginine and the majority of patients had stimulated GH peak below standard cut-off levels for GHD (GHRH-Arg <4.1 µg/L; all other tests <3 µg/L).
• Patients in the lowest GH peak concentration group started on a lower GH dose than the other groups (Table 1) , although there were no between-group differences at later times.
• Patients with the lowest stimulated GH peak concentration had lower IGF-I (Table 1) suggesting more severe GHD, and were more likely to have multiple pituitary hormone deficiencies (Figure 2 ). • Baseline means for BMI, serum lipids, smoking status and Framingham CVD risk did not differ between the categories of stimulated GH peak concentration (Table 2) . Mean BMI, serum lipid values and Framingham CVD risk during follow-up did not differ between the GH peak concentration groups. • More patients in the lowest GH peak concentration group reported hyperlipidemia (Table 3 ).
• Treatment-emergent adverse events were reported by similar numbers of patients in each GH peak concentration group. Serious adverse events were reported more frequently in the patients with the lowest stimulated GH peak concentration, but the only system organ class that differed significantly between groups was infections and infestations (Table 4) .
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CONCLUSIONS
In adult GH-deficient patients in HypoCCS in Italy, those with stimulated peak GH concentration in the lowest 33 rd percentile:
• were more likely to have multiple pituitary hormone deficiencies, indicating more severe GH deficiency • had the lowest mean starting dose of GH • had hyperlipidemia reported more frequently • reported serious adverse events more frequently.
OBJECTIVE
The aim of the present analysis was to describe the characteristics and outcomes of the Italian adult patients with hypopituitarism/GHD who are participating in HypoCCS.
PATIENTS and METHODS
Patients entered into the HypoCCS database meet the criteria for the adult indication for Humatrope ® , according to the approved package insert. The onset of GHD could have been either during childhood (CO) or during adulthood (AO). As an observational study, diagnosis and treatment were at the discretion of the investigating physician. Data were assessed for Italian patients in the HypoCCS database for the data lock of July 2010. Patients with evaluable data were grouped according to tertiles (Group A ≤33%, Group B >33-≤66%, Group C >66%) of maximum GH peak concentration reported from stimulation testing at the time of entry to the study. Patients were also assessed according to body mass index (BMI) category (≤25, >25-≤30, >30 kg/m 2 ). Baseline demographic and other patient characteristics were analyzed. GH dose, BMI, serum lipid concentrations, smoking status and CVD risk according to the Framingham index were analyzed at baseline and over time of GH treatment, at yearly intervals.
Statistics
Differences between groups for baseline parameters were examined by analysis of variance (ANOVA). Between-group differences during follow-up were examined by analysis of covariance (ANCOVA), including treatment group and baseline value as factors.
SUMMARY Group A N=342

Group B N=345
Group C N=338 P More patients in the lowest stimulated GH peak category reported serious adverse events during follow-up (Table 4 ). The only system organ class that differed significantly between the categories was infections and infestations. Among co-morbidities specified by the investigators, hyperlipidemia was reported more frequently for patients with the lowest stimulated peak GH concentration (Table 3 ). Other co-morbidities did not differ significantly between the groups. Patients with the lowest stimulated peak GH concentration had a lower mean IGF-I concentration and mean starting dose of GH and were treated for significantly longer (Table 1 ). There were no significant between-group differences for maximum GH dose at later times. 
RESULTS
• The HypoCCS database included 1025 patients in Italy with data available for analysis. The most frequent cause of hypopituitarism/GHD was pituitary adenoma reported for 40% of patients, with craniopharyngiomas reported for 14% and idiopathic GHD reported for 13% (34% in CO and 6% in AO patients).
MPHD was reported more frequently by patients with the lowest stimulated GH peak concentration (Figure 2 ). BMI and other factors associated with cardiovascular risk did not differ between the groups categorized by stimulated GH peak concentration, at baseline (Table 2) or during follow-up (not shown).
